You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
Vebreltinib's Third Indication for NSCLC with MET Amplification was Officially Accepted by China CDE and Granted as Priority Review
Author：Avistone
Time：2024-12-25
On December 25, 2024, Avistone announced that its wholly-owned subsidiary, Beijing Pearl Biotechnology Co., Ltd., submitted a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for a new indication of Vebreltinib (PLB-1001). This application has been officially accepted by CDE and granted as priority review. The proposed indication is for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET amplification. This milestone indicates that the field of NSCLC with MET Amplification is expected to enter a new era of precision-targeted therapy.
